Literature DB >> 10436868

Antileukotrienes and laboratory models of asthma.

S C Lazarus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10436868     DOI： 10.1007/BF02737606

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN： 1080-0549            Impact factor:   8.667


× No keyword cloud information.
  68 in total

1.  Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist.

Authors:  P J Manning; R M Watson; D J Margolskee; V C Williams; J I Schwartz; P M O'Byrne
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

2.  Intolerance to aspirin. Clinical studies and consideration of its pathogenesis.

Authors:  M Samter; R F Beers
Journal:  Ann Intern Med       Date:  1968-05       Impact factor: 25.391

3.  The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.

Authors:  S C Lazarus; H H Wong; M J Watts; H A Boushey; B J Lavins; M C Minkwitz
Journal:  Am J Respir Crit Care Med       Date:  1997-12       Impact factor: 21.405

4.  Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval.

Authors:  E A Bronsky; J P Kemp; J Zhang; D Guerreiro; T F Reiss
Journal:  Clin Pharmacol Ther       Date:  1997-11       Impact factor: 6.875

5.  Lower threshold and greater bronchomotor responsiveness of asthmatic subjects to sulfur dioxide.

Authors:  D Sheppard; W S Wong; C F Uehara; J A Nadel; H A Boushey
Journal:  Am Rev Respir Dis       Date:  1980-12

6.  Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro.

Authors:  C S Spada; A L Nieves; A H Krauss; D F Woodward
Journal:  J Leukoc Biol       Date:  1994-02       Impact factor: 4.962

7.  The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

Authors:  B Dahlén; M Kumlin; D J Margolskee; C Larsson; H Blomqvist; V C Williams; O Zetterström; S E Dahlén
Journal:  Eur Respir J       Date:  1993-07       Impact factor: 16.671

8.  Airway constriction in normal humans produced by inhalation of leukotriene D. Potency, time course, and effect of aspirin therapy.

Authors:  J W Weiss; J M Drazen; E R McFadden; P Weller; E J Corey; R A Lewis; K F Austen
Journal:  JAMA       Date:  1983-05-27       Impact factor: 56.272

9.  Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.

Authors:  K Sladek; A Szczeklik
Journal:  Eur Respir J       Date:  1993-03       Impact factor: 16.671

10.  Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge.

Authors:  K Sladek; R Dworski; J Soja; J R Sheller; E Nizankowska; J A Oates; A Szczeklik
Journal:  Am J Respir Crit Care Med       Date:  1994-04       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.